Heart Health Ingredients - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The heart health ingredients market size was valued at USD 9.41 billion in 2025 and estimated to grow from USD 9.95 billion in 2026 to reach USD 13.13 billion by 2031, at a CAGR of 5.74% during the forecast period (2026-2031). This report is Segmented by Type (Omega 3 Fatty Acids, Beta Glucan, Phytosterols, and More), by Source (Plant-Based, Animal-Based, Algae-Based, and Others), by Form (Powder, Liquid, and Others), by Application (Dietary Supplements, Functional Food and Beverage, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Heart Health Ingredients Market Trends and Insights

Rising prevalence of cardiovascular diseases globally

Cardiovascular diseases (CVDs) represent a significant global health challenge, driving substantial growth in the heart health ingredients market. These diseases, which include coronary artery disease, stroke, and hypertension, are the primary cause of mortality worldwide. The prevalence of CVDs has increased due to sedentary lifestyles, unhealthy dietary habits, tobacco use, and rising rates of obesity and diabetes. As consumers become more aware of these health risks, they increasingly seek heart-healthy products, including functional foods, dietary supplements, and nutraceuticals. These products contain beneficial ingredients, including omega-3 fatty acids, phytosterols, fiber (beta-glucan), and antioxidants such as polyphenols, which help manage cholesterol levels, blood pressure, and overall cardiovascular health. The World Health Organization (WHO) data illustrates the magnitude of this health crisis, with cardiovascular diseases causing approximately 338,000 deaths in Germany, 222,700 in Italy, and 161,200 in Poland as of 2023. These statistics, even from countries with sophisticated healthcare systems, have prompted governments and health organizations worldwide to emphasize the importance of preventive healthcare measures.

Increasing aging population and associated heart health concerns

The aging global population drives the demand for heart health ingredients as older adults face higher cardiovascular risks and seek preventive healthcare solutions. Key factors influencing this trend include increased life expectancy, lower birth rates, and medical advancements. In 2023, Japan reported the highest proportion of people aged 65 years or above at 30% of its population, followed by Italy at 24%, according to World Bank data. The older demographic demonstrates higher supplement consumption and increased investment in preventive health measures, creating a strong market for evidence-based heart health ingredients. This age group also shows greater engagement with regular health screenings and preventive care protocols. Population forecasts indicate similar aging patterns across developed markets, with the 65+ age group expected to double by 2050 in many regions due to improved healthcare infrastructure and lower mortality rates.

Competition from conventional pharmaceutical products

Healthcare providers and consumers prefer drug therapies over nutritional interventions for managing cardiovascular risks. Medical professionals choose proven cardiovascular medications with clear dosing protocols, especially for high-risk patients who need immediate treatment. Bayer's KERENDIA (finerenone), approved by the FDA in 2025 for heart failure treatment, reduced cardiovascular death and heart failure events by 16%, showing how pharmaceuticals compete with nutritional approaches. Insurance companies cover pharmaceutical treatments more readily than nutritional supplements, which creates cost barriers for consumers interested in heart health ingredients. Drugs must undergo extensive Phase III trials, while supplements need only observational studies and smaller clinical trials. However, increasing focus on preventive healthcare and high cardiovascular treatment costs creates opportunities for heart health ingredients to serve as complementary therapies rather than primary treatments.

Other drivers and restraints analyzed in the detailed report include:

• Growing consumer awareness about preventive healthcare
• Integration of heart health ingredients in everyday food products
• Stringent regulatory requirements for ingredient approval and health claims

Segment Analysis

Omega-3 fatty acids hold a dominant 35.62% market share in 2025, supported by strong consumer awareness and extensive clinical research validating their cardiovascular benefits. Coenzyme Q10 shows the highest growth potential with a projected CAGR of 6.86% through 2031, supported by research in heart failure treatment and cellular energy production. Beta-glucan maintains consistent market growth, supported by Food and Drug Administration (FDA) approved health claims for LDL cholesterol reduction. Phytosterols benefit from regulatory support, with approved coronary heart disease risk reduction claims in the United States and European Union.

Protein ingredients, including plant and dairy sources, show increasing demand among older consumers for their dual benefits in muscle maintenance and cardiovascular health. Technological developments in bioavailability enhancement and delivery systems are improving product effectiveness and user compliance. For instance, in October 2024, DSM-Firmenich launched Life's DHA B54-0100, an omega-3 formulation containing 545 mg of DHA per gram, enabling reduced capsule sizes to address consumption challenges in omega-3 supplementation.

Plant-based sources hold a 55.94% market share in 2025, as consumers increasingly prefer sustainable and familiar ingredient origins. Algae-based alternatives show significant growth potential with a projected 7.03% CAGR through 2031. Animal-based sources experience declining preference due to sustainability concerns and dietary restrictions, though they remain important for applications requiring specific bioavailability profiles. Marine-derived ingredients show varied performance, with traditional fish oil facing sustainability challenges while algae cultivation emerges as an environmentally sustainable alternative.

The transition to algae-based sources marks a significant change in omega-3 production, addressing sustainability and quality requirements. Schizochytrium cultivation produces high DHA concentrations in controlled environments, eliminating risks of marine biotoxins and heavy metal contamination. Plant-based ingredient development continues to expand, with Tiger nut oil receiving European Food Safety Authority (EFSA) approval for its oleic acid content and cardiovascular benefits.

Complete Report Scope:

• By Type
  • Omega-3 Fatty Acids
  • Beta-Glucan
  • Phytosterols
  • Protein
  • Coenzyme Q10
  • Others
• By Source
  • Plant-based
  • Animal-based
  • Algae-based
  • Others
• Form
  • Powder
  • Liquid
  • Others
• By Application
  • Dietary Supplements
  • Functional Food and Beverage
  • Pharmaceuticals
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Netherlands
    • Poland
    • Belgium
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Indonesia
    • South Korea
    • Thailand
    • Singapore
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • Egypt
    • Morocco
    • Turkey
    • Rest of Middle East and Africa

Geography Analysis

North America holds 37.98% market share in 2025, supported by clear regulations, robust healthcare systems, and high public awareness of cardiovascular health risks. Companies like Cargill and Archer Daniels Midland Company utilize the region's manufacturing capabilities and regulatory expertise for global distribution. However, market maturity and increased regulatory oversight limit growth opportunities beyond traditional supplement markets.

Asia-Pacific registers the highest growth rate at 7.08% CAGR through 2031, driven by increasing cardiovascular disease incidence and growing middle-class healthcare expenditure. Regional health challenges, including air pollution, changing dietary patterns, and high hypertension rates, increase ingredient demand across multiple applications. The region expands manufacturing capacity through strategic partnerships, while regulatory alignment efforts improve market access for global suppliers.

Europe maintains consistent growth, supported by strict regulations that boost consumer trust in heart health ingredients while restricting unproven products. The region's aging population and comprehensive healthcare systems promote preventive nutrition adoption, especially in Nordic countries with developed functional food markets. Post-Brexit regulatory differences require manufacturers to comply with separate European Union and United Kingdom frameworks. Additionally, the European Union Deforestation Regulation (EUDR) influences ingredient sourcing practices across the food and supplement sectors.

List of Companies Covered in this Report:

• Cargill, Incorporated
• DSM-Firmenich AG
• Archer Daniels Midland Company
• BASF SE
• Kerry Group plc
• Tate and Lyle PLC
• Evonik Industries AG
• Croda International Plc
• Super Beta Glucan Inc.
• Marinova Pty Ltd
• Aker BioMarine ASA
• BENEO GmbH
• Chemcopia Ingredients Pvt Ltd
• Glanbia plc
• Lonza Group AG
• Bunge Limited
• Elementa Ingredients
• Epax Norway AS
• Vinayak Ingredients Pvt. Ltd.
• Novozymes A/S

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support